0.8701
Immunic Inc Aktie (IMUX) Neueste Nachrichten
Immunic showcases Phase 2 data on vidofludimus calcium at ACTRIMS Forum - Proactive financial news
HC Wainwright Reaffirms "Buy" Rating for Immunic (NASDAQ:IMUX) - MarketBeat
IMUX: HC Wainwright & Co. Reiterates Buy Rating with $8 Target | - GuruFocus
Is Immunic Inc attractive for institutional investorsInsider Buying & Fast Exit Strategy with Risk Control - baoquankhu1.vn
Brookline Cap M Predicts Immunic FY2025 Earnings - MarketBeat
Immunic (NASDAQ:IMUX) Upgraded at Brookline Cap M - MarketBeat
Analysts Set Expectations for Immunic FY2025 Earnings - MarketBeat
Immunic (NASDAQ:IMUX) Upgraded at Brookline Capital Management - Defense World
Brookline Capital Management Upgrades Immunic (NASDAQ:IMUX) to "Strong-Buy" - MarketBeat
Immunic to present additional data on MS drug at ACTRIMS forum - Investing.com Nigeria
Small cap wrap: Fineqia, Immunic, M2i Global, Trust Stamp… - Proactive Investors
Immunic to present additional data on MS drug at ACTRIMS forum By Investing.com - Investing.com South Africa
Immunic to present additional Phase 2 data on vidofludimus calcium in progressive MS - Proactive financial news
MS trial: Immunic therapy cuts brain lesions and EBV signals - Stock Titan
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis - Sahm
Buyback Watch: Is Sandisk Corporation stock a top performer YTDPortfolio Gains Report & Target Return Focused Stock Picks - baoquankhu1.vn
Immunic, Inc. (NASDAQ:IMUX) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Chipmakers Recap: Is Immunic Inc stock a good dividend stockJuly 2025 Reactions & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
Fed Meeting: Is Immunic Inc stock a good dividend stockWeekly Market Outlook & AI Driven Price Forecasts - baoquankhu1.vn
Insider Traders Lose US$42k As Immunic Drops - simplywall.st
Immunic (NASDAQ:IMUX) Trading Down 2.1%Here's Why - MarketBeat
Published on: 2026-01-29 08:29:42 - baoquankhu1.vn
Buy Signal: Whats next for DRTSW stockWeekly Earnings Recap & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Aug Sentiment: Should value investors consider Immunic Inc2025 Earnings Surprises & Weekly High Return Stock Opportunities - baoquankhu1.vn
Published on: 2026-01-18 02:31:06 - baoquankhu1.vn
Market Recap: Whats next for Immunic Inc stockPortfolio Value Report & Real-Time Price Movement Reports - baoquankhu1.vn
Valuation Update: What is Immunic Incs book value per share2025 Earnings Surprises & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Aug Outlook: Can Immunic Inc stock maintain growth trajectoryEarnings Miss & Fast Gain Swing Alerts - Bộ Nội Vụ
Immunic (IMUX) Reviews 2025 Performance and Highlights Upcoming Milestones, Shares Up 24.10% - Finviz
Immunic targets MS market with Phase 3 dataICYMI - Proactive financial news
Published on: 2026-01-09 20:07:43 - ulpravda.ru
Can Immunic Inc. stock beat market expectations this quarterTrade Entry Report & AI Driven Stock Price Forecasts - Улправда
Earnings Update: Will Immunic Inc stock see insider buyingJuly 2025 Drop Watch & Consistent Income Trade Recommendations - Bộ Nội Vụ
How Immunic Inc. stock performs in high volatility marketsJuly 2025 Macro Moves & Weekly Hot Stock Watchlists - ulpravda.ru
Can Immunic Inc. stock maintain operating marginsJobs Report & Consistent Profit Trade Alerts - ulpravda.ru
Will Immunic Inc. stock see insider buyingJuly 2025 Volume & High Accuracy Investment Entry Signals - ulpravda.ru
Why Immunic Inc. (10VA) stock appears on watchlists2025 Buyback Activity & Long-Term Growth Portfolio Plans - ulpravda.ru
Will Immunic Inc. stock keep outperforming rivals2025 Growth vs Value & Reliable Entry Point Alerts - Улправда
Immunic (NASDAQ:IMUX) Given Buy Rating at D. Boral Capital - Defense World
D. Boral Capital Reaffirms Buy Rating for Immunic (NASDAQ:IMUX) - MarketBeat
IMUX: D. Boral Capital Maintains 'Buy' Rating with $8 Price Targ - GuruFocus
Immunic looks to 2026 data as late-stage MS program advances - Proactive financial news
Immunic CEO on key 2025 highlights and 2026 milestones - Proactive financial news
EQS-News: Immunic AG: Immunic Highlights 2025 Accomplishments and Upcoming Milestones - FinanzNachrichten.de
Immunic Highlights 2025 Accomplishments and Upcoming Milestones - PR Newswire
Immunic, Inc. (NASDAQ:IMUX) Given Consensus Rating of "Buy" by Analysts - MarketBeat
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):